- Home
- ACET vs AIRG Comparison
ACET vs AIRG Comparison
Compare ACET & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- AIRG
- Stock Information
- Founded
- ACET 1947
- AIRG 1995
- Country
- ACET United States
- AIRG United States
- Employees
- ACET N/A
- AIRG N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- AIRG Radio And Television Broadcasting And Communications Equipment
- Sector
- ACET Health Care
- AIRG Technology
- Exchange
- ACET Nasdaq
- AIRG Nasdaq
- Market Cap
- ACET 55.1M
- AIRG 48.7M
- IPO Year
- ACET N/A
- AIRG 2016
- Fundamental
- Price
- ACET $0.75
- AIRG $3.98
- Analyst Decision
- ACET Buy
- AIRG Strong Buy
- Analyst Count
- ACET 6
- AIRG 2
- Target Price
- ACET $6.00
- AIRG $9.25
- AVG Volume (30 Days)
- ACET 768.4K
- AIRG 11.1K
- Earning Date
- ACET 05-06-2025
- AIRG 05-07-2025
- Dividend Yield
- ACET N/A
- AIRG N/A
- EPS Growth
- ACET N/A
- AIRG N/A
- EPS
- ACET N/A
- AIRG N/A
- Revenue
- ACET N/A
- AIRG $58,381,000.00
- Revenue This Year
- ACET N/A
- AIRG N/A
- Revenue Next Year
- ACET N/A
- AIRG $23.54
- P/E Ratio
- ACET N/A
- AIRG N/A
- Revenue Growth
- ACET N/A
- AIRG 8.46
- 52 Week Low
- ACET $0.45
- AIRG $3.17
- 52 Week High
- ACET $1.70
- AIRG $10.34
- Technical
- Relative Strength Index (RSI)
- ACET 56.33
- AIRG 48.15
- Support Level
- ACET $0.64
- AIRG $3.85
- Resistance Level
- ACET $0.72
- AIRG $4.35
- Average True Range (ATR)
- ACET 0.06
- AIRG 0.20
- MACD
- ACET 0.01
- AIRG -0.00
- Stochastic Oscillator
- ACET 74.37
- AIRG 28.68
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.